Tirzepatide vs semaglutide: what's actually different.

If you have spent any time researching GLP-1 medications for weight loss, you have run into the same comparison everywhere: tirzepatide versus semaglutide. The headline claim — that tirzepatide produces more weight loss — is roughly correct in clinical trial averages, but it is also incomplete in ways that matter for the actual decision a man makes about which medication to start.

This walks through what is actually different between the two. The mechanisms. The trial data on weight loss. The side effect profiles. The muscle-loss question, which is real and underdiscussed. Cost and access in the current market. And the brand-name versus generic-name picture, which gets confusing fast (Zepbound, Wegovy, Mounjaro, Ozempic — all of these are at play).

A note up front. Neither medication is universally better. They are different tools, and the right tool depends on factors a clinician should walk through with you — including medical history, what your insurance covers, what is available through the pharmacy you would be working with, and what your tolerance is for the trade-offs each medication brings.

Tirzepatide vs semaglutide: quick comparison

Tirzepatide and semaglutide are both injectable peptide medications used for weight loss and, depending on indication, type 2 diabetes. Both are taken weekly. Both produce their effects through the gut-brain hormone system rather than through stimulants or appetite suppressants in the older sense.

The core difference is what they bind to. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist. The dual-agonist design produces somewhat different effects on appetite, glucose handling, and body composition. In trial settings, average weight loss with tirzepatide has been higher than with semaglutide. In real-world practice, individual response varies considerably, and many men do well on either medication.

How tirzepatide and semaglutide work

Semaglutide mimics the natural gut hormone GLP-1 (glucagon-like peptide-1), which the body releases in response to eating. GLP-1 slows gastric emptying, reduces appetite signals from the gut to the brain, and supports glucose-dependent insulin release. Sustained activation of the GLP-1 receptor through a long-acting medication produces meaningful reductions in food intake and body weight in most people who respond.

Tirzepatide does the same thing on GLP-1, and adds activation of a second receptor: GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone, and the role of GIP receptor activation in weight loss is the subject of ongoing research, but the practical outcome of dual agonism in clinical trials has been larger average weight loss compared to single-receptor GLP-1 agonism. The SURMOUNT-1 trial of tirzepatide for chronic weight management documents the dual-receptor effect on weight loss in a non-diabetic population.

Which may lead to more weight loss?

On clinical trial averages, tirzepatide has produced greater weight loss than semaglutide in head-to-head and indirect comparisons. In the SURMOUNT-1 trial, participants on the highest tirzepatide dose lost an average of around 20 percent of body weight over 72 weeks. In the STEP-1 trial of semaglutide, participants on 2.4mg weekly lost an average of around 15 percent of body weight over 68 weeks. Different trials, different populations, but a real difference in the averages.

The averages do not tell the individual story, however. Some men lose substantially more than the trial average on either medication. Some men lose substantially less. Response is shaped by adherence, dose escalation, lifestyle context, and what appears to be genuine biological variability that is not yet fully predictable. A man who loses 25 percent of body weight on semaglutide is not unusual. A man who loses 10 percent on tirzepatide is also not unusual. The averages should anchor expectations, not determine them.

Side effects: semaglutide vs tirzepatide

The two medications share most of their side effect profile because they share the GLP-1 mechanism. Nausea is the most common, particularly in the first few weeks and during dose escalation. Constipation, diarrhea, and reflux are common. Fatigue and reduced energy are reported by many men in the early weeks. Most of these side effects fade as the body adjusts, particularly after the dose stabilizes.

Where the two differ slightly: tirzepatide's dual-agonism appears to be associated with somewhat different gastrointestinal patterns in some patients, with mixed reports on whether it is gentler or more pronounced overall — the data is less clear-cut than the weight-loss comparison. Hair shedding from rapid weight loss occurs with both, through the same telogen effluvium mechanism. The hair-shedding pattern is shared across the GLP-1 class.

Rare but serious side effects to be aware of with both: pancreatitis, gallbladder issues, and severe gastroparesis. Both medications carry a class warning around medullary thyroid carcinoma based on rodent data, and should not be used in people with a personal or family history of MTC or MEN 2 syndrome. A clinician review covers these screening questions before prescribing.

Muscle loss and nutrition during GLP-1 treatment

This is the section most ranking pages either skip or bury, and it deserves more attention than it usually gets. Significant weight loss from any source — diet, surgery, GLP-1 medication — produces a mix of fat loss and lean tissue loss. The split varies, but lean tissue (muscle) typically accounts for somewhere between 20 and 40 percent of total weight lost in unstructured weight loss, and that share is higher when protein intake is inadequate and resistance training is absent.

GLP-1 medications can amplify this because they reduce appetite to a degree that often makes adequate protein intake harder than it would be on a normal eating pattern. Men who are not actively focused on protein and resistance training during GLP-1 weight loss tend to lose more muscle than men who are. The lost muscle is partly metabolically active tissue, which can make weight maintenance harder later.

The practical fix is to aim for higher-than-default protein during GLP-1 weight loss — typically 0.8 to 1.0 grams of protein per pound of target body weight — and to include resistance training two to three times per week. Both of these reduce the share of weight lost as muscle and improve body composition outcomes. They also reduce the severity of telogen effluvium during the same period.

Cost and access: what affects pricing

Brand-name semaglutide (Wegovy for weight loss; Ozempic for diabetes) and brand-name tirzepatide (Zepbound for weight loss; Mounjaro for diabetes) typically cost around $1,000 per month at retail without insurance. With manufacturer cash-pay programs or insurance coverage, the actual cost varies widely.

Compounded versions of both medications have existed in the U.S. cash-pay market, with compounded tirzepatide and compounded semaglutide typically running $200 to $500 per month depending on dose, pharmacy, and what is bundled. The regulatory situation around compounded GLP-1 medications has shifted multiple times since 2024 and continues to evolve. Our breakdown of compounded tirzepatide pricing covers the current market structure.

Insurance coverage is uneven. Diabetes indications (Ozempic, Mounjaro) are more commonly covered than weight-loss-only indications (Wegovy, Zepbound). For cash-paying patients, the practical comparison is often between branded retail at $1,000 a month or compounded at a fraction of that — with all of the regulatory trade-offs compounded preparations involve.

Zepbound vs Wegovy: how the brand names compare

Zepbound is Eli Lilly's brand name for tirzepatide indicated for chronic weight management. Wegovy is Novo Nordisk's brand name for semaglutide indicated for chronic weight management. Both are FDA-approved specifically for weight loss in patients meeting certain BMI criteria, with or without weight-related comorbidities. Both are taken once weekly by injection.

From a clinical comparison standpoint, Zepbound vs Wegovy is the same as tirzepatide vs semaglutide — same molecules, same mechanisms, same trial data. The brand names exist because the same molecules are sold under different brand names depending on the FDA-approved indication. Pricing for Wegovy and Zepbound is similar at retail, with manufacturer cash-pay programs available for both at varying terms.

Mounjaro vs Ozempic: how the brand names compare

Mounjaro is Eli Lilly's brand name for tirzepatide indicated for type 2 diabetes. Ozempic is Novo Nordisk's brand name for semaglutide indicated for type 2 diabetes. Both produce significant weight loss as a side effect of glycemic control, and both have been widely used off-label for weight loss in addition to their on-label diabetes use.

For type 2 diabetes patients, Mounjaro and Ozempic are both well-supported by clinical evidence, and the choice often comes down to insurance coverage, individual response, and clinician preference. Ozempic specifically for prediabetes is a more targeted question covered separately. The off-label use of Mounjaro and Ozempic for weight loss has been a major driver of the GLP-1 market expansion, alongside the on-label weight loss indications of Zepbound and Wegovy.

Which one is better?

There is no universally better medication between the two. There are situations where one is more appropriate than the other.

Tirzepatide tends to make more sense when: maximum weight loss potential is the primary goal, the patient tolerates the dual-agonism profile well, cost or access favors tirzepatide in the patient's specific market, or the response to semaglutide has been inadequate. Tirzepatide also tends to be the more common modern compounded option in cash-pay markets.

Semaglutide tends to make more sense when: the patient has done well on it before, insurance coverage favors semaglutide, the side effect profile of tirzepatide has not been tolerated well, or the dose escalation pace of tirzepatide has been a problem. Semaglutide has the longer real-world track record, which some men and clinicians weigh.

The honest answer for most men starting GLP-1 therapy for the first time is that either medication is a reasonable starting point with clinician oversight, and the right answer for you depends on the factors a clinician should walk through with you in the intake.

When to talk to a clinician

GLP-1 medications are not over-the-counter substances and should not be started without clinician review. The clinical screening covers personal and family history of medullary thyroid carcinoma and MEN 2 syndrome, history of pancreatitis, severe gastroparesis, gallbladder disease, current medication interactions, and pregnancy or pregnancy planning.

It is also worth a clinician conversation if you are on a GLP-1 medication and noticing concerning symptoms — severe abdominal pain, persistent vomiting, signs of dehydration, vision changes, or thyroid-area swelling. These are not common, but they are worth flagging quickly when they happen. Maro's intake is built around clinician review, and changes to your prescription happen through a licensed physician rather than a refill flow.

Frequently asked questions

Is tirzepatide better than semaglutide for weight loss?

Tirzepatide tends to produce greater weight loss than semaglutide in clinical trial averages — typically around 20 percent of body weight at the highest dose versus around 15 percent for semaglutide. Individual results vary substantially, however, and many men do well on either medication. Whether tirzepatide is the better choice depends on cost, access, side effect tolerance, and a clinician's assessment of your specific situation.

Can you switch from semaglutide to tirzepatide?

Yes, switching from one to the other is reasonable and is sometimes recommended by clinicians when the response to the first medication has been inadequate or when side effects have been hard to tolerate. The switch should happen under clinician guidance, with appropriate dose adjustment and timing. Both medications have their own escalation schedules, and starting the second at the wrong level after stopping the first can amplify side effects.

Do tirzepatide and semaglutide have the same side effects?

The side effect profiles overlap substantially because both medications act on the GLP-1 receptor. Nausea, constipation, diarrhea, reflux, and fatigue are common with both, particularly during dose escalation. Tirzepatide's dual-agonism produces somewhat different gastrointestinal patterns in some patients, but the differences are subtle compared to the shared profile. Both carry similar warnings around pancreatitis and medullary thyroid carcinoma history.

Which is cheaper, tirzepatide or semaglutide?

At brand-name retail, both medications cost roughly $1,000 per month. With manufacturer cash-pay programs or insurance coverage, the price varies. In the compounded cash-pay market, both medications have been available at $200 to $500 per month depending on the program. Tirzepatide and semaglutide are generally priced similarly within each market segment, with variation coming more from the program structure than the medication itself.

Are compounded versions of these medications the same?

Compounded versions contain the same active ingredient as the brand-name medications — compounded tirzepatide is the same molecule as Zepbound and Mounjaro, compounded semaglutide is the same molecule as Wegovy and Ozempic — but the finished compounded preparations are not FDA-approved finished products. They are made by licensed compounding pharmacies under separate regulatory frameworks. The active ingredient is the same, but the finished product has not gone through FDA product approval.